Denali Therapeutics
DNLI
45 hedge funds and large institutions have $909M invested in Denali Therapeutics in 2017 Q4 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
64.56% more ownership
Funds ownership: 0% → 64.56% (+65%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Crestline Management
Fort Worth,
Texas
|
+$370M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$168M |
| 3 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$160M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$88.5M |
| 5 |
Temasek Holdings
Singapore
|
+$79.3M |
Top Sellers
DNLI Hedge Fund Activity: Q4 2017 in Review
45 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q4 2017, worth a combined $909M.
Buyers outnumbered sellers: 45 funds opened new DNLI positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Crestline Management, opening a new position worth an estimated $370M.
- 45 institutional investors held Denali Therapeutics (DNLI) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $909M of Denali Therapeutics stock for Q4 2017.
- 45 funds opened new Denali Therapeutics positions in Q4 2017 and 0 closed out, a net change of +45 holders.
- The largest Denali Therapeutics buyer in Q4 2017 was Crestline Management, an estimated $370M added.
Based on aggregated 13F filings for Q4 2017.